Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A pilot plant-based dietary intervention in overweight and obese patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma- the Nutrition Prevention (NUTRIVENTION) study
    Meeting Abstract

    Shah, U. A.; Alicea, D.; Adintori, P. A.; Burge, M.; Blaslov, J.; Derkach, A.; Mailankody, S.; Korde, N.; Tan, C.; Hultcrantz, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-1
    Meeting Abstract

    Sebag, M.; Raje, N. S.; Bahlis, N. J.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study
    Meeting Abstract

    Patel, K.; Zonder, J. A.; Sano, D.; Maris, M.; Lesokhin, A.; von Keudell, G.; Lai, C.; Ramchandren, R.; Catalano, T.; Lin, G. H. Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • BTG1 mutation promotes aggressive lymphoma development by lowering the threshold to MYC activation and generating "super-competitor" B cells
    Meeting Abstract

    Mlynarczyk, C.; Teater, M.; Pae, J.; Arulraj, T.; Chin, C. R.; Wang, L.; Ersching, J.; Kots, E.; Chadburn, A.; Barin, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Updated results from CARTITUDE-1: Phase 1b/2study of ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Martin, T.; Usmani, S. Z.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Hari, P.; Avigan, D.; Deol, A.; Htut, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The genomic landscape of Waldenström Macroglobulinemia reveals sustained germinal center activity and late-developing copy number aberrations
    Meeting Abstract

    Maclachlan, K. H.; Bagratuni, T.; Kastritis, E.; Ziccheddu, B.; Lu, S. X.; Yellapantula, V. D.; Famulare, C.; Diamond, B.; Chojnacka, M.; Raj, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Targeting PRAME with TCR-mimic CAR T cells in AML
    Meeting Abstract

    Loeb, A. M.; Castro, S.; Nourigat-Mckay, C.; Perkins, L.; Pardo, L.; Leonti, A. R.; Tang, T. T.; Call, L. F.; Hylkema, T. A.; Scheinberg, D. A.; more...
    Blood (2021)

    Fulltext@MSK | Save